Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017133523) USE OF METHOXATIN, DERIVATIVE AND/OR SALT THEREOF IN SJOGREN'S SYNDROME AND PHARMACEUTICAL COMPOSITION
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/133523 International Application No.: PCT/CN2017/072130
Publication Date: 10.08.2017 International Filing Date: 22.01.2017
IPC:
A61K 31/4745 (2006.01) ,A61P 1/02 (2006.01) ,A61P 27/02 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
4738
ortho- or peri-condensed with heterocyclic ring systems
4745
condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1
Drugs for disorders of the alimentary tract or the digestive system
02
Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27
Drugs for disorders of the senses
02
Ophthalmic agents
Applicants:
南京舒鹏生物科技有限公司 NANJING SHUPENG LIFESCIENCE CO., LTD [CN/CN]; 中国江苏省南京市鼓楼区清凉门大街金信花园13幢43号401室 Room 401, Jinxin Garden Building 13 Unit 43, Qingliangmen Avenue, Gulou District Nanjing, Jiangsu 210024, CN
Inventors:
温传俊 WEN, Chuanjun; CN
孙奋勇 SUN, Fenyong; CN
Agent:
深圳壹舟知识产权代理事务所(普通合伙) SHENZHEN ARK INTELLECTUAL PROPERTY AGENT LLP; 中国广东省深圳市 罗湖区爱国路1058号金通大厦B栋2011室 B2011, Jintong Building, No. 1058, Aiguo Road, Luohu Shenzhen, Guangdong 518003, CN
Priority Data:
201610080478.904.02.2016CN
Title (EN) USE OF METHOXATIN, DERIVATIVE AND/OR SALT THEREOF IN SJOGREN'S SYNDROME AND PHARMACEUTICAL COMPOSITION
(FR) UTILISATION DE MÉTHOXATINE, D'UN DÉRIVÉ ET/OU D'UN SEL DE CETTE DERNIÈRE CONTRE LE SYNDROME DE GOUGEROT-SJÖGREN, ET COMPOSITION PHARMACEUTIQUE
(ZH) 吡咯喹啉醌、其衍生物和/或盐在干燥综合征中的用途以及药用组合物
Abstract:
(EN) The present invention relates to use of methoxatin of formula (I), a derivative and/or a salt thereof (PQQ) in the preparation of a medication for treating and/or preventing primary Sjogren's syndrome, secondary Sjogren's syndrome as well as dry mouth, dry eye and multiple system damages procured by the involvement of other exocrine glands and other organs outside the glands caused by Sjogren's syndrome, in formula (I), R1, R2 and R3 being same or different, each independently representing lower alkyl, lower alkenyl, lower alkynyl, aralkyl, alkaryl, phenyl, a hydrogen atom, sodium atom or a potassium atom; and PQQ or pharmaceutical combinations of PQQ combined with active vitamin D, NAC, resveratrol, epigallocatechin gallate, curcumin, anthocyanin, vitamin E, vitamin C, or vitamin D and the like. The medicament and the pharmaceutical combinations can treat Sjogren's syndrome and associated diseases which are derivative of Sjogren's syndrome. The present invention can remove excess oxygen radicals in the body, inhibit NF-kB activation caused by oxidative stress, and inhibit autoimmunity, thereby reducing the inflammatory response of Sjogren's syndrome.
(FR) La présente invention concerne l'utilisation de méthoxatine, de formule (I), d'un dérivé et/ou d'un sel de cette dernière (PQQ) dans la préparation d'un médicament pour traiter et/ou prévenir le syndrome de Gougerot-Sjögren primitif, le syndrome de Gougerot-Sjögren secondaire ainsi que la sécheresse buccale, la sécheresse oculaire et les multiples dommages systémiques résultant de l'implication d'autres glandes exocrines et d'autres organes en dehors des glandes impliquées dans le syndrome de Gougerot-Sjögren, dans la formule (I), R1, R2 et R3 étant identiques ou différents, représentant chacun indépendamment un alkyle à chaîne courte, un alcényle à chaîne courte, un alkynyle à chaîne courte, un aralkyle, un alkaryle, un phényle, un atome d'hydrogène, un atome de sodium ou un atome de potassium; ainsi que la PQQ ou des combinaisons pharmaceutiques combinant la PQQ à la forme active de la vitamine D, à la NAC, au resvératrol, au gallate d'épigallocatéchine, à la curcumine, à l'anthocyane, à la vitamine E, à la vitamine C, à la vitamine D, et similaire. Le médicament et les combinaisons pharmaceutiques peuvent traiter le syndrome de Gougerot-Sjögren et les maladies associées qui dérivent du syndrome de Gougerot-Sjögren. La présente invention peut éliminer l'excès de dérivés radicalaires de l'oxygène présents dans le corps, inhiber l'activation de NF-kB induite par le stress oxydatif, et inhiber l'auto-immunité, permettant ainsi de diminuer la réponse inflammatoire du syndrome de Gougerot-Sjögren.
(ZH) 本发明涉及式(I)吡咯喹啉醌、其衍生物和/或盐(PQQ)在制备用于治疗和/或预防原发性干燥综合征、继发性干燥综合征以及由干燥综合征引起的口干、眼干以及其他外分泌腺及腺体外其他器官的受累而出现多系统损害的药物中的应用,其中,式(I)中,R1、R2和R3相同或不同,分别单独表示低级烷基、低级烯基、低级炔基、芳烷基、烷芳基、苯基、氢原子、钠原子或钾原子;以及PQQ或PQQ联合活性维生素d、NAC、白藜芦醇、表没食子儿茶素没食子酸酯、姜黄素、花青素、维生素E、维生素C或维生素D等的药物组合,该药物及药物组合可以治疗干燥综合征以及与干燥综合征相关的适应症。本发明能够清除体内多余的氧自由基,抑制氧化应激导致的NF-kB激活,抑制自身免疫,从而减少干燥综合征的炎症反应。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)
Also published as:
IN201817027634EP3412292US20190030024